Pembrolizumab versus brentuximab vedotin for relapsed or refractory classical Hodgkin lymphoma

The multinational phase 3 study KEYNOTE-204 evaluated pembrolizumab monotherapy versus brentuximab vedotin for relapsed or refractory classical Hodgkin lymphoma. Interim analysis of the study found that the pembrolizumab group had statistically significant and clinically meaningful longer progression-free survival (13.2 months versus 8.3 months; HR 0.65; p=0.0027), with safety consistent with previous reports.